PLATFORM TECHNOLOGY

In quest of one of the most powerful, yet elusive biomarkers of our time – tumour-associated Circulating Endothelial Cells (tCEC) – X-ZELL has developed a powerful platform technology capable of analysing blood samples and frozen tissue at a whole new level of detail.

Perfected in a real life as part of our daily laboratory work in Thailand and Singapore, X-ZELL’s rare cell detection platform is the centrepiece of our ongoing investigation into the potential of tCEC as novel biomarkers for clinically significant, early-stage cancers and has spawned a series of spin-off systems that are available for Research Use Only.

Two of the system’s three core modules are currenly available for Research Use Only – the X-ZELL Cryoimmunostaining™ Suite as well as the corresponding microscopy toolkit (learn more and order here).

They will soon be complemented by Module I, the X-ZELL hMX™ Cell Separator, which is set to launch in Q2’21, also for Research Use Only.

Going forward, X-ZELL will gradually upgrade the image acquisition module (Module III) by automating the slide scanning process and deploying Artificial Intelligence (AI) to automatically identify and visualise atypical cells.

In the future, we hope to be able to automatically cross-reference the findings with our ever-growing database of cancer cell images, nicknamed X-ZELL Cloud Atlas

Unless specifically indicated, all X-ZELL products and services are for Research Use Only and not for therapeutic or diagnostic use.

MODULE IA – hMX™ Lysis

X-ZELL’s proprietary hMX™ Lysis assay was designed to remove 99.9% of red blood cells from a whole blood sample without compromising atypical cell yield. Using proprietary buffers exclusive to X-ZELL, it is capable of retaining 8 out of 10 target cells. The assay is currently available in select markets for Research Use Only. Please contact X-ZELL for more information.

MODULE IB – hMX™Cell Separation

High-flow magnetic cell separation has established itself as the gold standard of modern cell separation. Existing systems, however, are limited by high internal ferromagnetic matrices that can cause non-specific cell retention during the separation process. X-ZELL’s patented, buffer-optimised, high-gradient magnetic cell separation (hMX™) system avoids non-specific binding by competitively blocking non-specific binding sites. With flow channels several hundred micrometres wide, it is the world’s only high-flow magnetic cell separation system capable of recovering large cells and even cell clumps. To be launched for Research Use Only in Q2’21.

MODULE II – Cryoimmunostaining™ SUITE

Comprised of two novel laboratory instruments, the Cryofixator™ and the Cryostainer™, X-ZELL’s patented Cryoimmunostaining™ Suite allows researchers to apply up to nine fluorophores at a time to cells fixated on standard laboratory slides – making it one of the most powerful cytology tools in the world today. The system is currently available in select markets for Research Use Only.
Please contact X-ZELL for more information.

Learn More | Order

MODULE III – Automated Microscopic Analysis

As opposed to competing technologies, X-ZELL’s rare cell detection technology is able to provide users with visual evidence of the target cells or cell clumps – in turn enabling classic cancer pathology at the single cell level.

To visualise all key characteristics of atypical cells – including as aneuploidy, polyploidy, as well as the expression of stem cell, mesenchymal, epithelial, cell proliferation and apoptotic markers – we recommend the use of a semi-automated widefield fluorescence microscope featuring a standard high-pressure mercury vapour arc-discharge light source, state-of-the-art monochrome CCD or sCMOS cameras as well as optimised filter sets available through X-ZELL (contact us for a full list of available upgrade kits). 

Using X-ZELL’s filter kit and proprietary software, standardized image acquisition times of as little as 50ms per channel are possible. 

X-ZELL

FIGHTING CANCER,
ONE CELL AT A TIME.

© 2021 X-ZELL INC

Find Us

XZELL HQ